JP2025166834A5 - - Google Patents

Info

Publication number
JP2025166834A5
JP2025166834A5 JP2025123756A JP2025123756A JP2025166834A5 JP 2025166834 A5 JP2025166834 A5 JP 2025166834A5 JP 2025123756 A JP2025123756 A JP 2025123756A JP 2025123756 A JP2025123756 A JP 2025123756A JP 2025166834 A5 JP2025166834 A5 JP 2025166834A5
Authority
JP
Japan
Prior art keywords
polypeptide
ebv
amino acid
acid sequence
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025123756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025166834A (ja
Filing date
Publication date
Priority claimed from JP2020554517A external-priority patent/JP7614842B2/ja
Application filed filed Critical
Publication of JP2025166834A publication Critical patent/JP2025166834A/ja
Publication of JP2025166834A5 publication Critical patent/JP2025166834A5/ja
Pending legal-status Critical Current

Links

JP2025123756A 2018-04-03 2025-07-24 抗原性エプスタインバーウイルスポリペプチド Pending JP2025166834A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862652201P 2018-04-03 2018-04-03
US62/652,201 2018-04-03
JP2020554517A JP7614842B2 (ja) 2018-04-03 2019-04-02 抗原性エプスタインバーウイルスポリペプチド
PCT/US2019/025419 WO2019195314A2 (en) 2018-04-03 2019-04-02 Antigenic epstein barr virus polypeptides
JP2023145164A JP7719134B2 (ja) 2018-04-03 2023-09-07 抗原性エプスタインバーウイルスポリペプチド

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2023145164A Division JP7719134B2 (ja) 2018-04-03 2023-09-07 抗原性エプスタインバーウイルスポリペプチド

Publications (2)

Publication Number Publication Date
JP2025166834A JP2025166834A (ja) 2025-11-06
JP2025166834A5 true JP2025166834A5 (cg-RX-API-DMAC7.html) 2026-03-18

Family

ID=66821298

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020554517A Active JP7614842B2 (ja) 2018-04-03 2019-04-02 抗原性エプスタインバーウイルスポリペプチド
JP2023145164A Active JP7719134B2 (ja) 2018-04-03 2023-09-07 抗原性エプスタインバーウイルスポリペプチド
JP2025123756A Pending JP2025166834A (ja) 2018-04-03 2025-07-24 抗原性エプスタインバーウイルスポリペプチド

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020554517A Active JP7614842B2 (ja) 2018-04-03 2019-04-02 抗原性エプスタインバーウイルスポリペプチド
JP2023145164A Active JP7719134B2 (ja) 2018-04-03 2023-09-07 抗原性エプスタインバーウイルスポリペプチド

Country Status (5)

Country Link
US (4) US11617780B2 (cg-RX-API-DMAC7.html)
EP (1) EP3773708A2 (cg-RX-API-DMAC7.html)
JP (3) JP7614842B2 (cg-RX-API-DMAC7.html)
CN (1) CN112512566A (cg-RX-API-DMAC7.html)
WO (1) WO2019195314A2 (cg-RX-API-DMAC7.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
ES3005559T3 (en) * 2018-07-20 2025-03-14 Aicuris Anti Infective Cures Ag Methods for screening and identifying agents that inhibit or modulate the nuclear egress complex of herpesviruses
MA55321A (fr) 2019-03-15 2022-01-19 Modernatx Inc Vaccins à base d'arn contre le vih
CN111154803B (zh) * 2020-01-10 2022-07-22 新乡医学院 一种重组EBV gHgL免疫原的制备方法及其应用
US20230145420A1 (en) * 2020-04-10 2023-05-11 Vanderbilt University Recombinant vaccines and methods of use thereof
US20210322483A1 (en) 2020-04-16 2021-10-21 Ichilov Tech Ltd. Cell-derived particles presenting heterologous cd24 and use thereof in therapy
CN113144187B (zh) * 2021-01-28 2024-03-22 安徽智飞龙科马生物制药有限公司 一种含EB病毒gHgLgp42蛋白的自组装纳米颗粒及其制备方法与应用
JP2024514183A (ja) * 2021-04-13 2024-03-28 モデルナティエックス インコーポレイテッド エプスタイン-バーウイルスmRNAワクチン
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN116143949A (zh) * 2023-02-23 2023-05-23 中山大学 一种水痘-带状疱疹病毒疫苗及其制备方法
WO2025186459A1 (en) * 2024-03-08 2025-09-12 Sanofi Antigenic epstein barr virus polypeptides
WO2025215618A1 (en) * 2024-04-12 2025-10-16 Seqirus Inc. Methods and reagents for treating or preventing ebv
WO2026117519A1 (en) * 2024-11-27 2026-06-04 Merck Sharp & Dohme Llc Nanoemulsion adjuvant compositions for epstein barr virus vaccines
WO2026128536A1 (en) * 2024-12-12 2026-06-18 Merck Sharp & Dohme Llc Liposomal adjuvant compositions for epstein barr virus vaccines
CN120365380B (zh) * 2025-04-21 2026-05-15 易康生物(苏州)有限公司 一种嵌合设计的eb病毒抗原及其应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0312164A1 (en) * 1987-10-16 1989-04-19 Merck & Co. Inc. Purification of recombinant epstein-barr virus antigens from vero cells, yeast cells or L cells
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
US6218371B1 (en) 1998-04-03 2001-04-17 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
WO2001075436A1 (en) 2000-04-03 2001-10-11 Board Of Trustees Of The Leland Stanford Junior University A method for protein structure alignment
EP1311540B1 (en) 2000-08-18 2007-12-19 Research Foundation Of State University Of New York Altered ospa of borrelia burgdorferi
US7097841B2 (en) 2002-05-10 2006-08-29 New Century Pharmaceuticals, Inc. Ferritin fusion proteins for use in vaccines and other applications
US7774185B2 (en) 2004-09-14 2010-08-10 International Business Machines Corporation Protein structure alignment using cellular automata
US20070196389A1 (en) 2005-11-18 2007-08-23 The Ohio State University Research Foundation Viral gene products and methods for vaccination to prevent viral associated diseases
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US7951770B2 (en) 2007-06-13 2011-05-31 Northwestern University Peptides, peptidomimetics and small molecule inhibitors of the Epstein-Barr virus mediated fusion and entry process
US20100285051A1 (en) 2007-12-21 2010-11-11 Dominique Ingrid Lemoine Vaccine
US20110117131A1 (en) 2008-04-09 2011-05-19 Ning Huang Production of OspA for Lyme Disease Control
US8623375B2 (en) 2010-05-14 2014-01-07 Baxter International Inc. Chimeric OspA genes, proteins, and methods of use thereof
WO2012006180A1 (en) 2010-06-29 2012-01-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hiv immunogens
EP2608806B1 (en) 2010-08-25 2017-10-25 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) An epstein-barr-virus vaccine
US20140186371A1 (en) * 2011-04-07 2014-07-03 Guriqbal S. Basi Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
EP2515112B1 (en) 2011-04-22 2015-08-12 Sysmex Corporation Method for electrochemically detecting analyte
JP5795184B2 (ja) * 2011-04-22 2015-10-14 国立大学法人 奈良先端科学技術大学院大学 被検物質の電気化学的検出方法
US20140348865A1 (en) 2011-09-12 2014-11-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. Immunogens based on an hiv-1 v1v2 site-of-vulnerability
WO2013044203A2 (en) 2011-09-23 2013-03-28 THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPTARTMENT OF HEALTH & HUMAN SERVICES Novel influenza hemagglutinin protein-based vaccines
EP2877205A4 (en) * 2012-07-26 2016-04-06 Jackson H M Found Military Med VACCINE WITH A MULTIMED FUSION PROTEIN AND IMMUNOTHERAPY
WO2014018931A1 (en) 2012-07-26 2014-01-30 The General Hospital Corporation Methods and compositions for treating autoimmune disease
EP4421177A3 (en) 2013-03-13 2024-12-18 The United States of America, as represented by the Secretary, Department of Health and Human Services Prefusion rsv f proteins and their use
EP3054971B1 (en) 2013-10-11 2021-03-10 The United States of America, represented by the Secretary, Department of Health and Human Services Epstein-barr virus vaccines
US9907844B2 (en) 2013-12-11 2018-03-06 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Human herpesvirus trimeric glycoprotein B, protein complexes comprising trimeric gB and their use as vaccines
CZ2014320A3 (cs) 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
US10363301B2 (en) 2014-05-27 2019-07-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Stabilized influenza hemagglutinin stem region trimers and uses thereof
BR112017014219A2 (en) 2014-12-31 2018-03-06 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services multivalent nanoparticle-based vaccines
US9703095B2 (en) 2015-01-05 2017-07-11 Edward Pakhchyan Light modulator for MEMS display
EP3048114A1 (en) 2015-01-22 2016-07-27 Novartis AG Cytomegalovirus antigens and uses thereof
US10301377B2 (en) 2015-02-24 2019-05-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
MX2018006785A (es) 2015-12-04 2018-11-09 Dana Farber Cancer Inst Inc Vacunacion con el dominio alfa 3 de mica/b para el tratamiento del cancer.
CN115960263A (zh) 2016-03-29 2023-04-14 美国政府(由卫生和人类服务部的部长所代表) 取代修饰的融合前rsv f蛋白及其用途
CN109310749B (zh) 2016-06-07 2022-09-23 德国癌症研究中心 Hpv l2肽免疫原性的改善
KR102724939B1 (ko) 2016-06-17 2024-11-01 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 선형 또는 분지형 폴리아크릴산 폴리머 아쥬반트를 포함하는 신규한 면역원성 제형
EP3474893A1 (en) * 2016-06-27 2019-05-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
CA3050914A1 (en) 2017-01-27 2018-08-02 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Vaccine compositions of herpesvirus envelope protein combinations to induce immune response
EP3612562A2 (en) * 2017-04-19 2020-02-26 Institute for Research in Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
WO2019014569A1 (en) 2017-07-13 2019-01-17 City Of Hope EXPRESSION SYSTEM FOR EXPRESSING GLYCOPROTEIN COMPLEXES OF HERPESVIRUS
US11964006B2 (en) 2017-09-16 2024-04-23 City Of Hope Multivalent Epstein-Barr virus-like particles and uses thereof
MA50813A (fr) * 2017-11-21 2020-09-30 Modernatx Inc Vaccins contre le virus d'epstein-barr
WO2019161163A1 (en) 2018-02-16 2019-08-22 The Wistar Institute Of Anatomy And Biology Epstein-barr virus nucleic acid constructs and vaccines made therefrom, and methods of using same
JP7614841B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性呼吸器合胞体ウイルスポリペプチド
CN112584858A (zh) 2018-04-03 2021-03-30 赛诺菲 抗原性ospa多肽
EP3773698A1 (en) 2018-04-03 2021-02-17 Sanofi Ferritin proteins
JP2021519600A (ja) 2018-04-03 2021-08-12 サノフイSanofi 抗原性インフルエンザ−フェリチンポリペプチド
CN112512566A (zh) 2018-04-03 2021-03-16 赛诺菲 抗原性爱泼斯坦-巴尔病毒多肽
AU2021356220A1 (en) 2020-10-08 2023-06-15 Virothera Limited Vaccine compositions
WO2023288090A1 (en) 2021-07-16 2023-01-19 California Institute Of Technology Stoichiometric expression of messenger polycistrons

Similar Documents

Publication Publication Date Title
JP2023179457A5 (cg-RX-API-DMAC7.html)
JP2023179436A5 (cg-RX-API-DMAC7.html)
JP2024054136A5 (cg-RX-API-DMAC7.html)
Weber Amino acid sequence studies on the tryptic peptides of the coat protein of the bacteriophage R17
JP2023512824A5 (cg-RX-API-DMAC7.html)
JP2018171063A5 (cg-RX-API-DMAC7.html)
JP2024041747A5 (cg-RX-API-DMAC7.html)
JP2018537087A5 (cg-RX-API-DMAC7.html)
JP2023517293A5 (cg-RX-API-DMAC7.html)
JP2022513308A5 (cg-RX-API-DMAC7.html)
JP2003501022A5 (cg-RX-API-DMAC7.html)
JP2003510050A5 (cg-RX-API-DMAC7.html)
JP2024505274A5 (cg-RX-API-DMAC7.html)
JP2022539560A5 (cg-RX-API-DMAC7.html)
FI4034555T3 (fi) Dap10/dap12-fuusiopolypeptidit
JP2002517193A5 (cg-RX-API-DMAC7.html)
EP3916005A3 (en) Immunogenic composition
JP2004532037A5 (cg-RX-API-DMAC7.html)
JP2006503088A5 (cg-RX-API-DMAC7.html)
JP2008517998A5 (cg-RX-API-DMAC7.html)
JP2023544300A5 (cg-RX-API-DMAC7.html)
RU2017104284A (ru) Выделенные полипептиды cd44 и их применение
JP2003334088A5 (cg-RX-API-DMAC7.html)
JP2024504136A5 (cg-RX-API-DMAC7.html)
JP2023510544A5 (cg-RX-API-DMAC7.html)